uniQure Gestione

Gestione criteri di controllo 1/4

uniQure Il CEO è Matt Kapusta, nominato in Dec2016, e ha un mandato di 7.92 anni. la retribuzione annua totale è $ 6.58M, composta da 9.6% di stipendio e 90.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.67% delle azioni della società, per un valore di € 1.79M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 7.2 anni.

Informazioni chiave

Matt Kapusta

Amministratore delegato

US$6.6m

Compenso totale

Percentuale dello stipendio del CEO	9.6%
Mandato del CEO	7.9yrs
Proprietà del CEO	0.7%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	7.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Matt Kapusta rispetto agli utili di uniQure?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$285m
Mar 31 2024	n/a	n/a	-US$297m
Dec 31 2023	US$7m	US$635k	-US$308m
Sep 30 2023	n/a	n/a	-US$228m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$157m
Dec 31 2022	US$6m	US$609k	-US$127m
Sep 30 2022	n/a	n/a	-US$125m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$324m
Dec 31 2021	US$5m	US$583k	US$330m
Sep 30 2021	n/a	n/a	US$321m
Jun 30 2021	n/a	n/a	US$303m
Mar 31 2021	n/a	n/a	-US$139m
Dec 31 2020	US$4m	US$585k	-US$125m
Sep 30 2020	n/a	n/a	-US$166m
Jun 30 2020	n/a	n/a	-US$136m
Mar 31 2020	n/a	n/a	-US$124m
Dec 31 2019	US$4m	US$548k	-US$124m
Sep 30 2019	n/a	n/a	-US$105m
Jun 30 2019	n/a	n/a	-US$103m
Mar 31 2019	n/a	n/a	-US$92m
Dec 31 2018	US$3m	US$502k	-US$83m
Sep 30 2018	n/a	n/a	-US$90m
Jun 30 2018	n/a	n/a	-US$78m
Mar 31 2018	n/a	n/a	-US$78m
Dec 31 2017	US$4m	US$468k	-US$79m

Compensazione vs Mercato: La retribuzione totale di Matt ($USD 6.58M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 782.05K ).

Compensazione vs guadagni: La retribuzione di Matt è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Matt Kapusta (52 yo)

7.9yrs

Mandato

US$6,584,919

Compensazione

Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Matthew Kapusta	CEO & Executive Director	7.9yrs	US$6.58m	0.67% € 1.8m
Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	3.4yrs	US$2.12m	0.16% € 421.1k
Richard Porter	Chief Business & Scientific Officer	1.1yrs	US$2.62m	0.068% € 184.4k
Jeannette Potts	Chief Legal & Compliance Officer and Corporate Secretary	1.5yrs	US$2.54m	0.022% € 60.6k
Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	no data	Nessun dato	Nessun dato
Amin Abujoub	Chief Technical Operations	less than a year	Nessun dato	Nessun dato
Tamara Tugal	Business Development Director	16.4yrs	Nessun dato	Nessun dato
Erin Boyer	Chief People & Culture Officer	less than a year	Nessun dato	Nessun dato
Walid Abi-Saab	Chief Medical Officer	1.4yrs	Nessun dato	0.24% € 639.7k
Eileen Sawyer	Vice President of Global Medical Affairs	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di UQ1 non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Matthew Kapusta	CEO & Executive Director	9.8yrs	US$6.58m	0.67% € 1.8m
Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	10.3yrs	Nessun dato	Nessun dato
Leonard Post	Independent Non-Executive Director	4.4yrs	US$412.46k	0.033% € 88.8k
Michael Hayden	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Katherine High	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jack Kaye	Independent Non-Executive Director	8.4yrs	US$424.96k	0.013% € 36.1k
Jesús Prieto	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Robin Ali	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Madhavan Balachandran	Independent Non-Executive Director	7.2yrs	US$412.46k	0.049% € 131.9k
Jeremy Springhorn	Independent Non-Executive Director	7.2yrs	US$424.96k	0.049% € 131.9k
David Meek	Independent Chairman of the Board	6.4yrs	US$444.96k	0.042% € 112.4k
Robert Gut	Non-Executive Director	6.1yrs	US$404.96k	0.091% € 245.1k

7.2yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di UQ1 sono considerati esperti (durata media dell'incarico 7.2 anni).

uniQure Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Uniqure N.V. Announces Executive Changes

uniQure N.V., Annual General Meeting, Jun 18, 2024

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold €163k worth of stock

uniQure N.V. Announces Executive Changes

CEO & Executive Director recently sold €465k worth of stock

Recent updates

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Third quarter 2024 earnings released: US$0.91 loss per share (vs US$1.88 loss in 3Q 2023)

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.16 loss per share (vs US$1.44 loss in 2Q 2023)

Uniqure N.V. Announces Executive Changes

Now 22% overvalued

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$1.36 loss per share (vs US$1.63 loss in 1Q 2023)

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold €163k worth of stock

Full year 2023 earnings released: US$6.47 loss per share (vs US$2.71 loss in FY 2022)

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Now 25% undervalued after recent price drop

Third quarter 2023 earnings released: US$1.88 loss per share (vs US$1.02 loss in 3Q 2022)

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Second quarter 2023 earnings released: US$1.44 loss per share (vs US$0.84 loss in 2Q 2022)

uniQure N.V. Announces Executive Changes

New major risk - Share price stability

First quarter 2023 earnings released: US$1.63 loss per share (vs US$1.00 loss in 1Q 2022)

CEO & Executive Director recently sold €465k worth of stock

Full year 2022 earnings released: US$2.71 loss per share (vs US$7.17 profit in FY 2021)

CEO & Executive Director recently sold €142k worth of stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Third quarter 2022 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Chief Operating Officer recently sold €95k worth of stock

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021)

uniQure N.V., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CEO & Executive Director recently sold €152k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

CEO & Executive Director recently sold €175k worth of stock

Investor sentiment deteriorated over the past week

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020)

President of Research & Development recently sold €271k worth of stock

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020)

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. (NasdaqGS:QURE) entered into a definitive agreement to acquire Corlieve Therapeutics SAS for €250 million.

Independent Non-Executive Chairman Philip Astley-Sparke has left the company

uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

Forecast to breakeven in 2021

No longer forecast to breakeven

uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector

First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020)

uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program

CEO, CFO & Executive Director recently sold €152k worth of stock

Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019)

Revenue misses expectations